Artificial Intelligence-enabled Management of Atrial Fibrillation(ABLE-AF Trial)
Artificial Intelligence-enabled Management of Atrial Fibrillation: a Randomized Clinical Trial (ABLE-AF Trial)
Atrial fibrillation (AF) is the most common type of irregular heartbeat in adults. People with AF may also have other heart problems, including reduced heart pumping function or diseases affecting the heart muscle or heart valves. Identifying these problems early is important because the condition of the heart can affect treatment decisions and long-term care.
An ultrasound examination of the heart, called transthoracic echocardiography (TTE) or an echocardiogram, is commonly used to check how well the heart pumps blood and to look for structural problems, such as heart valve disease. However, an echocardiogram requires special equipment and trained healthcare professionals to perform and interpret the examination. Because of these requirements, it may not always be available when needed. This can be particularly challenging in situations where heart function needs to be evaluated quickly, such as when a patient with AF has a very fast heart rate. Delays may also occur in outpatient settings because of limited availability of echocardiography.
Artificial intelligence (AI) technology may provide an additional way to identify patients who are more likely to have heart problems and who may benefit from further evaluation. A standard 12-lead electrocardiogram (ECG) is a simple and widely available test that records the electrical activity of the heart. AI-based computer programs can analyze information contained in an ECG that may not be easily recognized through routine interpretation.
This study will use two AI-based ECG programs, called AiTiALVSD and AiTiALVDD. AiTiALVSD analyzes a standard 12-lead ECG to identify patients who may have reduced heart pumping function. Previous studies have evaluated this program in different clinical settings, including patients with AF and a fast heart rate.
AiTiALVDD analyzes the ECG for signs that may be associated with difficulty in the heart relaxing and filling with blood. Problems with heart relaxation and filling may occur in several types of heart disease, including heart valve disease, abnormal thickening of the heart muscle, heart disease related to high blood pressure, diseases affecting the heart muscle, and coronary artery disease. Importantly, some patients may have these conditions even when the heart's overall pumping function is normal. Therefore, evaluating only pumping function may not identify all patients who have important underlying heart disease.
By using AiTiALVSD and AiTiALVDD together, this study aims to evaluate a broader AI-based approach to identifying heart problems in patients with AF. AiTiALVSD may help identify patients who are more likely to have reduced heart pumping function, while AiTiALVDD may provide additional information about possible problems with heart relaxation and filling. A high-risk result from AiTiALVDD may serve as a signal that further heart evaluation should be considered, including evaluation for significant heart valve disease or other underlying structural heart conditions.
The purpose of this study is to evaluate whether using these two AI-based ECG programs together can help identify patients with AF who may have previously unrecognized problems with heart function or underlying heart disease. Patients identified by the AI analysis as being at higher risk may receive further evaluation as appropriate to determine whether additional heart disease is present.
The study will also evaluate the clinical usefulness of this AI-based ECG approach in routine care. The goal is not to replace an echocardiogram or a physician's clinical assessment. Instead, AI-based ECG analysis may serve as an additional screening tool to help healthcare professionals identify patients who may benefit from further cardiac testing.
By using information from a routinely performed ECG, this approach may help support earlier and more efficient evaluation of heart function and underlying heart disease in patients with AF. The results of this study will help determine whether combining AiTiALVSD and AiTiALVDD can provide useful information for deciding which patients may need additional cardiac evaluation and whether this approach can improve the process of identifying clinically important heart conditions.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Jong IL Choi, Ph.D
- Telefonní číslo: 82-10-2122-5476
- E-mail: stabler92@gmail.com
Studijní záloha kontaktů
- Jméno: Eunjin Ahn
- Telefonní číslo: 82-10-2540-4608
- E-mail: chloe.ahn@trinitycro.com
Studijní místa
-
-
-
Seoul, Jižní Korea, 02841
- Korea University Anam Hospital
-
Kontakt:
- Jong-Il Choi
- Telefonní číslo: 82-10-2122-5476
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria
- Atrial fibrillation (AF) with rapid ventricular response confirmed on the day of screening or within 90 days before screening.
- Rapid ventricular response is defined as (i) a ventricular rate ≥110 bpm or (ii) a ventricular rate ≥100 bpm with related symptoms.
- AF can be confirmed by any guideline-accepted electrocardiographic (ECG) method, including 12-lead ECG, Holter ECG, or single-lead ECG (e.g., patch ECG or smartwatch).
- AF must be documented for at least 10 seconds on a 12-lead ECG or at least 30 seconds on Holter or single-lead ECG.
Exclusion Criteria
- Left ventricular ejection fraction (LV EF) assessed by transthoracic echocardiography (TTE) within the past 6 months.
- If TTE was performed at another institution within the past 6 months, this exclusion criterion applies only when objective imaging data confirming LV EF are available.
- Hemodynamically unstable patients requiring immediate direct current cardioversion.
- Acute decompensated heart failure requiring immediate hospitalization.
- Contraindication to AF pharmacotherapy (e.g., pregnancy).
- Hospitalization for acute myocardial infarction (STEMI or NSTEMI) within the past 3 months.
- 12-lead ECG not available in a format analyzable by the AI model.
- Individuals aged 18 years or younger.
- Diagnosis of severe valvular disease (e.g., severe aortic stenosis).
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Diagnostický
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Aktivní komparátor: Conventional Treatment
Pharmacologic treatment will be initiated after TTE is performed, in accordance with guideline recommendations.
|
|
|
Experimentální: AI-Guided Treatment
Guideline-directed AF pharmacotherapy may be initiated based on the AI-predicted LV EF obtained on the day of enrollment. Because patients with AF undergo a 12-lead ECG for clinical purposes, in the investigational group the AI-predicted LV EF becomes available immediately once the AI-enabled 12-lead ECG is performed.
|
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Major adverse cardiovascular events (MACE), a composite outcome
Časové okno: 1year
|
Major adverse cardiovascular events (MACE) will be assessed as a composite outcome comprising all-cause death, cardiovascular death, stroke (ischemic or hemorrhagic), acute coronary syndrome, and cardiovascular hospitalization. The outcome will be reported as the number of participants experiencing at least one of these events during the follow-up period. Participants experiencing multiple component events will be counted only once in the composite outcome. |
1year
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants with All-Cause Death
Časové okno: 1year
|
The number of participants who die from any cause during the follow-up period will be assessed. Each participant will be counted only once. Unit of Measure - Number of participants |
1year
|
|
Number of Participants with Stroke (Ischemic or Hemorrhagic)
Časové okno: 1year
|
The number of participants experiencing at least one ischemic or hemorrhagic stroke during the follow-up period will be assessed. Each participant will be counted only once, regardless of the number of stroke events. Unit of measure - number of participants |
1year
|
|
Number of Participants with Acute Myocardial Infarction
Časové okno: 1year
|
The number of participants experiencing at least one acute myocardial infarction during the follow-up period will be assessed. Each participant will be counted only once, regardless of the number of events. Unit of Measure- Number of participants |
1year
|
|
Number of Participants Hospitalized for Heart Failure
Časové okno: 1year
|
The number of participants experiencing at least one hospitalization for heart failure during the follow-up period will be assessed. Each participant will be counted only once, regardless of the number of hospitalizations. Unit of Measure- Number of participants |
1year
|
|
Number of Participants with an Emergency Room Visit or Hospitalization for Cardiovascular Causes
Časové okno: 1year
|
The number of participants experiencing at least one emergency room (ER) visit or hospitalization for cardiovascular causes during the follow-up period will be assessed. Participants experiencing both an ER visit and hospitalization for cardiovascular causes will be counted only once. Unit of Measure- Number of participants |
1year
|
|
Percentage of Participants Achieving Atrial Fibrillation Rate Control
Časové okno: 1year
|
Atrial fibrillation (AF) rate control will be assessed as the percentage of participants achieving a heart rate of less than 110 beats per minute (bpm) during the specified assessment period. Unit of Measure: Percentage of participants |
1year
|
|
Time to Achievement of Atrial Fibrillation Rate Control
Časové okno: 1year
|
Time to AF rate control will be measured in days from the protocol-defined starting point to the first documented achievement of a heart rate of less than 110 bpm. Unit of Measure: Days |
1year
|
|
Time to Initiation of Oral Antiarrhythmic Drug Therapy
Časové okno: 1year
|
Time to initiation of oral antiarrhythmic drug therapy will be measured in days from the protocol-defined starting point to the first documented initiation of oral antiarrhythmic drug therapy. Unit of Measure: Days |
1year
|
|
Time to Atrial Fibrillation Catheter Ablation
Časové okno: 1year
|
Time to atrial fibrillation (AF) catheter ablation will be measured in days from the protocol-defined starting point to the date of the first AF catheter ablation procedure. Unit of Measure: Days |
1year
|
|
Time to Restoration of Sinus Rhythm
Časové okno: 1year
|
Time to restoration of sinus rhythm will be measured in days from the protocol-defined starting point to the first documented restoration of sinus rhythm. Unit of Measure: Days |
1year
|
|
AUC for LV Systolic Dysfunction
Časové okno: 1year
|
The predictive performance of the artificial intelligence (AI) model for identifying left ventricular (LV) systolic dysfunction will be assessed using the area under the receiver operating characteristic curve (AUC). AUC values range from 0 to 1, with higher values indicating better discrimination. The AUC of the AI model will be compared with that of N-terminal pro-B-type natriuretic peptide (NT-proBNP). |
1year
|
|
Sensitivity for LV Systolic Dysfunction
Časové okno: 1year
|
Sensitivity of the AI model for identifying LV systolic dysfunction will be calculated as the percentage of participants with reference-standard-confirmed LV systolic dysfunction who are correctly identified by the AI model. Values range from 0% to 100%, with higher values indicating better sensitivity. |
1year
|
|
Specificity for LV Systolic Dysfunction
Časové okno: 1year
|
Specificity of the AI model for identifying LV systolic dysfunction will be calculated as the percentage of participants without reference-standard-confirmed LV systolic dysfunction who are correctly identified as negative by the AI model. Values range from 0% to 100%, with higher values indicating better specificity. |
1year
|
|
Positive Predictive Value
Časové okno: 1year
|
Positive predictive value (PPV) will be calculated as the percentage of participants with a positive AI prediction for LV systolic dysfunction who have reference-standard-confirmed LV systolic dysfunction. Values range from 0% to 100%, with higher values indicating greater positive predictive value. |
1year
|
|
Negative Predictive Value
Časové okno: 1year
|
Negative predictive value (NPV) will be calculated as the percentage of participants with a negative AI prediction for LV systolic dysfunction who do not have reference-standard-confirmed LV systolic dysfunction. Values range from 0% to 100%, with higher values indicating greater negative predictive value. |
1year
|
|
Atrial Fibrillation Burden at 1 Year Assessed by 3-Day Holter Electrocardiography
Časové okno: 1year
|
Atrial fibrillation (AF) burden at 1 year will be assessed using 3-day Holter electrocardiography (ECG) monitoring. AF burden will be calculated as the total duration of AF episodes divided by the total analyzable ECG monitoring time, multiplied by 100. AF burden will be expressed as a percentage, ranging from 0% to 100%, with higher percentages indicating greater AF burden. |
1year
|
|
Change From Baseline to 1 Year in Atrial Fibrillation-Related Quality of Life Assessed by the Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire (AFEQT)
Časové okno: Baseline and 1 year
|
Atrial fibrillation (AF)-related quality of life will be assessed using the Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire (AFEQT) at baseline and 1 year. The AFEQT overall score ranges from 0 to 100, with higher scores indicating better AF-related quality of life. Change from baseline will be calculated as the score at 1 year minus the baseline score. A positive change indicates an improvement in AF-related quality of life. |
Baseline and 1 year
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Publikace a užitečné odkazy
Obecné publikace
- Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010 Apr 15;362(15):1363-73. doi: 10.1056/NEJMoa1001337. Epub 2010 Mar 15.
- Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.
- Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):15-25. doi: 10.1161/CIRCEP.110.958033. Epub 2010 Dec 15.
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
- Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbuchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns HJGM, Breithardt G; EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29.
- Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ, Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL; CABANA Investigators. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019 Apr 2;321(13):1261-1274. doi: 10.1001/jama.2019.0693.
- Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, Roux JF, Yung D, Skanes A, Khaykin Y, Morillo C, Jolly U, Novak P, Lockwood E, Amit G, Angaran P, Sapp J, Wardell S, Lauck S, Macle L, Verma A; EARLY-AF Investigators. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2021 Jan 28;384(4):305-315. doi: 10.1056/NEJMoa2029980. Epub 2020 Nov 16.
- Kwon JM, Jo YY, Lee SY, Kang S, Lim SY, Lee MS, Kim KH. Artificial Intelligence-Enhanced Smartwatch ECG for Heart Failure-Reduced Ejection Fraction Detection by Generating 12-Lead ECG. Diagnostics (Basel). 2022 Mar 8;12(3):654. doi: 10.3390/diagnostics12030654.
- Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. No abstract available.
- Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.
- Kwon JM, Kim KH, Jeon KH, Kim HM, Kim MJ, Lim SM, Song PS, Park J, Choi RK, Oh BH. Development and Validation of Deep-Learning Algorithm for Electrocardiography-Based Heart Failure Identification. Korean Circ J. 2019 Jul;49(7):629-639. doi: 10.4070/kcj.2018.0446. Epub 2019 Mar 21.
- Lange S, Freitag G. Choice of delta: requirements and reality--results of a systematic review. Biom J. 2005 Feb;47(1):12-27; discussion 99-107. doi: 10.1002/bimj.200410085.
- Jeong JH, Baek YS, Park J, Park HW, Choi EK, Park JK, Kang KW, Kim J, Lee YS, Kim JB, Choi JI, Joung B, Shim J. Impact of Atrial Fibrillation with Rapid Ventricular Response on Atrial Fibrillation Recurrence: From the CODE-AF Registry. J Clin Med. 2024 Sep 14;13(18):5469. doi: 10.3390/jcm13185469.
- Bhat A, Khanna S, Chen HHL, Gan GCH, MacIntyre CR, Tan TC. Drivers of hospitalization in atrial fibrillation: A contemporary review. Heart Rhythm. 2020 Nov;17(11):1991-1999. doi: 10.1016/j.hrthm.2020.06.015. Epub 2020 Jun 19.
- Kim D, Yang PS, You SC, Sung JH, Jang E, Yu HT, Kim TH, Pak HN, Lee MH, Lip GYH, Joung B. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ. 2021 May 11;373:n991. doi: 10.1136/bmj.n991.
- Lim J, Lee MS, Suh JH, Kang S, Lee HS, Jang JH, Son JM, Kwon JM, Kim YJ, Kim KH, Lee SP. Artificial Intelligence-Enabled ECG for Elevated E/e' on Echocardiography: Hemodynamic Relevance and Prognostic Value. J Am Heart Assoc. 2026 May 5;15(9):e046989. doi: 10.1161/JAHA.125.046989. Epub 2026 Apr 28.
- Jeong JH, Kang S, Lee HS, Lee MS, Son JM, Kwon JM, Lee HS, Choi YY, Kim SR, Cho DH, Kim YG, Kim MN, Shim J, Park SM, Kim YH, Choi JI. Deep learning algorithm for predicting left ventricular systolic dysfunction in atrial fibrillation with rapid ventricular response. Eur Heart J Digit Health. 2024 Aug 19;5(6):683-691. doi: 10.1093/ehjdh/ztae062. eCollection 2024 Nov.
- Rahimi AR, York M, Gheewala N, Markson L, Hauser TH, Manning WJ. Trends in outpatient transthoracic echocardiography: impact of appropriateness criteria publication. Am J Med. 2011 Aug;124(8):740-6. doi: 10.1016/j.amjmed.2011.03.030.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- ABLE-AF Trial
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .